Plain-English translation of NCT06631287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help people who have long-term COVID recover from problems like brain fog, memory trouble, shortness of breath, and fatigue. is already used to treat other conditions and works by calming down the body's immune system. Researchers want to see if this medication can help your brain and heart/lung symptoms improve over time.
Millions of people around the world are struggling with long-term COVID—months or even years of exhaustion, thinking problems, and physical weakness that doctors don't yet have a good treatment for. This medication is being tested because early research suggests it might help reduce the inflammation in the body that causes these lasting symptoms.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to take either the study medication or a placebo (a pill with no active medicine) by mouth daily. You'll have regular visits with the study team to check how you're doing, answer questions about your symptoms, and possibly do some simple tests of your memory and physical ability. The study involves about 550 people total, and you would be part of understanding whether this treatment helps long-term COVID.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States